Highlights Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-04-29 am EDT			5-day change	1st Jan Change
17.58 ^HKD	-0.23%		+11.97%	-35.60%

Apr. 25	Ascentage Pharma to Present Four Studies at US Oncology Meet	MT
Apr. 09	Ascentage Pharma Chairman Boosts Stake in Firm	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascentage Pharma to Present Four Studies at US Oncology Meet	Apr. 25	MT
Ascentage Pharma Chairman Boosts Stake in Firm	Apr. 09	MT
Ascentage Pharma Group Directors Acquire Company Shares	Apr. 03	MT
Ascentage Pharma Widens Loss by Nearly 5% in 2023	Mar. 28	MT
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting	Mar. 05	CI
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia	Feb. 13	CI
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network	Jan. 16	CI
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib	Dec. 14	CI
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR	Dec. 10	CI
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication	Nov. 24	CI
China Approves Ascentage Pharma's Chronic-Phase Chronic Myeloid Leukemia Treatment	Nov. 19	MT
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients	Nov. 17	CI
Ascentage Pharma Trustee Repurchases Shares	Nov. 15	MT
Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM	Nov. 02	CI
Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports	Nov. 02	CI
Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc	23-10-23	CI
Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia	23-10-17	CI
Ascentage Pharma and AstraZeneca Investment Co., Ltd. Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL	23-10-15	CI
Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE	23-10-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Highlights

Filters